Positron Emission Tomography with ([11C]Methyl)-L-Methionine, [11C]D-Glucose, and [68Ga]EDTA in Supratentorial Tumors

Ericson, K.; Lilja, Anders; Bergström, Mats; Vp, Collins; Eriksson, L. S.; Ehrin, E.; H, von Holst; Lundqvist, Hans; Långsrom, B B; Mosskin, Mikael

doi:10.1097/00004728-198507010-00005

Cited by 150 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Angiogenesis and amino acid uptake are related (32). In many instances, the extent of increased 11 C-MET uptake is larger than that of contrast enhancement (33) and indicates tumor infiltration and tumor margins. Especially in low-grade gliomas, amino acid uptake is related to prognosis and survival (34,35).…”

Section: Petmentioning

confidence: 99%

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Heiss¹,

Raab²,

Lanfermann³

2011

J Nucl Med

124

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the differences in the information obtained by various MRI and PET modalities and (2) the best combination of imaging procedures to detect brain tumors, to define the biologic activity or malignancy of a tumor, to validate therapeutic effects, and to differentiate between recurrent tumor and tissue necrosis.Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNM designates each JNM continuing education article for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.For CE credit, participants can access this activity through the SNM Web site (http://www.snm.org/ce_online) through October 2012.Neuroimaging plays a significant role in the diagnosis of intracranial tumors, especially brain gliomas, and must consist of an assessment of location and extent of the tumor and of its biologic activity. Therefore, morphologic imaging modalities and functional, metabolic, or molecular imaging modalities should be combined for primary diagnosis and for following the course and evaluating therapeutic effects. MRI is the gold standard for providing detailed morphologic information and can supply some additional insights into metabolism (MR spectroscopy) and perfusion (perfusion-weighted imaging) but still has limitations in identifying tumor grade, invasive growth into neighboring tissue, and treatment-induced changes, as well as recurrences. These insights can be obtained by various PET modalities, including imaging of glucose metabolism, amino acid uptake, nucleoside uptake, and hypoxia. Diagnostic accuracy can benefit from coregistration of PET results and MRI, combining the high-resolution morphologic images with the biologic information. These procedures are optimized by the newly developed combination of PET and MRI modalities, permitting the simultaneous assessment of morphologic, functional, metabolic, and molecular information on the human brain. Brai n tumors are newly formed alterations of morphology, and for their diagnosis, therefore, CT or MRI is mandatory. These imaging modalities are essential for delineating the normal and pathologic anatomy and also for assessing vascular supply and impairment of the blood-brain barrier (BBB) (perfusion-weighted imaging; contrast enhancement). Additionally, MRI is capable of giving functional information on microstructural (diffusion-weighted imaging [DWI]), physiologic, and metabolic (MR spectroscopy [MRS]) changes of tumor tissues. PET and MRI provide physiologic, biochemical, and molecular information related to tumor metabolism, proliferation rate, invasiveness, and interaction with surrounding and remote areas-informati...

show abstract

Section: Petmentioning

confidence: 99%

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Heiss¹,

Raab²,

Lanfermann³

2011

J Nucl Med

124

View full text Add to dashboard Cite

show abstract

“…While in some cases of low-grade gliomas PET may show increased FDG uptake, in most cases FDG uptake is decreased [11,33,314], as in nontumoral lesions. In these cases, MET is very helpful, as the uptake of MET is increased in nearly all low-grade gliomas as well as in high-grade gliomas [319][320][321][322][323]. PET is, however, unsuccessful in differentiating between the various histological types of brain tumours, as high uptake of FDG is seen not only in gliomas but also in lymphomas [317,324,325], meningiomas [326], pituitary adenomas [327] and metastases [328].…”

Section: Differential Diagnosis When Lesions Are Demonstratedmentioning

confidence: 99%

“…Few studies have compared FDG and MET; they have demonstrated that FDG is probably better for establishing the degree of malignancy, whereas MET better delineates the lesions, especially low-grade gliomas [319,321,323,353,354].…”

Section: Differential Diagnosis When Lesions Are Demonstratedmentioning

confidence: 99%

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

Abstract. Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and followup. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved.

show abstract

“…The application of 18 F-FDG is based on an increased glycolysis and deficient respiratory rate in neoplastic cells (8,9). Meningiomas have been found to have high 18 F-FDG accumulation, equivalent to that of the cortical gray matter or low glucose metabolism (10,11). Glucose consumption of meningioma assessed by 18 F-FDG PET has been proposed as an index of tumor aggressivity and probability of recurrence (11).…”

mentioning

confidence: 99%

1-¹¹C-Acetate Versus ¹⁸F-FDG PET in Detection of Meningioma and Monitoring the Effect of γ-Knife Radiosurgery

Liu¹,

Chang²,

Guo³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

Positron Emission Tomography with ([11C]Methyl)-L-Methionine, [11C]D-Glucose, and [68Ga]EDTA in Supratentorial Tumors

Cited by 150 publications

References 0 publications

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

1-¹¹C-Acetate Versus ¹⁸F-FDG PET in Detection of Meningioma and Monitoring the Effect of γ-Knife Radiosurgery

Contact Info

Product

Resources

About

Positron Emission Tomography with ([11C]Methyl)-L-Methionine, [11C]D-Glucose, and [68Ga]EDTA in Supratentorial Tumors

Cited by 150 publications

References 0 publications

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

1-11C-Acetate Versus 18F-FDG PET in Detection of Meningioma and Monitoring the Effect of γ-Knife Radiosurgery

Contact Info

Product

Resources

About

1-¹¹C-Acetate Versus ¹⁸F-FDG PET in Detection of Meningioma and Monitoring the Effect of γ-Knife Radiosurgery